Larotrectinib Is Safe and Effective in TRK Fusion–Positive Primary CNS Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
Neuro-oncology 2021 Nov 27;[EPub Ahead of Print], F Doz, CM van Tilburg, B Geoerger, M Højgaard, I Øra, V Boni, M Capra, J Chisholm, HC Chung, SG DuBois, S Gallego-Melcon, NU Gerber, H Goto, JE Grilley-Olson, JR Hansford, DS Hong, A Italiano, HJ Kang, K Nysom, A Thorwarth, J Stefanowicz, M Tahara, DS Ziegler, IT Gavrilovic, R Norenberg, L Dima, E De La Cuesta, TW Laetsch, A Drilon, S PerreaultFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.